Literature DB >> 19895737

Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells.

Yun-Ge Zhao1, Ai-Zhen Xiao, Jian Ni, Yan-Gao Man, Qing-Xiang Amy Sang.   

Abstract

BACKGROUND AND
OBJECTIVE: Elevated expression of matrix metalloproteinases (MMPs) has been found in multiple carcinoma tissues. MMP-26 is highly expressed in prostate and breast cancer tissues, and promotes the invasion of human prostate cancer cells not only through the cleavage of fibronectin and type IV collagen but also by the activation of pro-MMP-9, a powerful gelatinase. This study was to present a comprehensive protein expression profile of MMP-26 in multiple human cancer tissues.
METHODS: The protein expression pattern of MMP-26 was examined using immunohistochemistry and multiple-tissue microarray. MMP-26 mRNA expression in coronary artery smooth muscle cells was detected by reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: The expression of MMP-26 in breast, colon, lung, brain, head and neck, prostate cancer, and melanoma tissues was significantly elevated when compared with parallel normal tissues (P<0.05), while not significantly elevated in kidney cancer, ovarian cancer, and non-Hodgkin's lymphoma (P>0.05). MMP-26 was also detected to express in gastric, rectal, thyroid, esophageal, and pancreatic cancers. MMP-26 protein was expressed in smooth muscle cells of the prostate and associated blood vessels. MMP-26 mRNA was also detected to express in human coronary artery smooth muscle cells.
CONCLUSIONS: MMP-26 expression may be associated with multiple human carcinomas, and it may serve as a molecular marker for the early diagnosis of these carcinomas. MMP-26 may also contribute to smooth muscle function in the human prostate and cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895737     DOI: 10.5732/cjc.008.10768

Source DB:  PubMed          Journal:  Ai Zheng


  7 in total

1.  MMP26: A potential biomarker for prostate cancer.

Authors:  Teng Cheng; Fei Li; Rui Wei; Meng-Qin Lv; Yin Zhou; Yun Dai; Yuan Yuan; Gui-Ying Jiang; Ding Ma; Qing-Lei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

Review 2.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

Review 3.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

Review 4.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17

5.  GM-CSF enhances tumor invasion by elevated MMP-2, -9, and -26 expression.

Authors:  Claudia M Gutschalk; Archana K Yanamandra; Nina Linde; Alice Meides; Sofia Depner; Margareta M Mueller
Journal:  Cancer Med       Date:  2012-11-26       Impact factor: 4.452

Review 6.  The present and future of prostate cancer urine biomarkers.

Authors:  Marina Rigau; Mireia Olivan; Marta Garcia; Tamara Sequeiros; Melania Montes; Eva Colás; Marta Llauradó; Jacques Planas; Inés de Torres; Juan Morote; Colin Cooper; Jaume Reventós; Jeremy Clark; Andreas Doll
Journal:  Int J Mol Sci       Date:  2013-06-17       Impact factor: 5.923

Review 7.  None-endoscopic Screening for Esophageal Squamous Cell Carcinoma- A Review.

Authors:  Gholamreza Roshandel; Shahryar Semnani; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2012-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.